Astellas Pays, And Pays Big, To Extend VelocImmune License With Regeneron
This article was originally published in The Pink Sheet Daily
Executive Summary
The Japanese pharma is paying $165 million upfront for continued access to the fully human monoclonal antibody discovery platform through 2018.